Related Experiment Videos
Decreased bradykinin binding sites in fibroblasts from progressive systemic scleroderma
1Department of Dermatology, Gifu University School of Medicine, Japan.
Archives of Dermatological Research
|January 1, 1994
Summary
Progressive systemic sclerosis (PSS) patients have fewer bradykinin receptors (BK-R) on skin cells, suggesting a post-translational issue. This finding may impact understanding and treatment of PSS by targeting BK-R levels.
Area of Science:
- Dermatology
- Molecular Biology
- Immunology
Background:
- Progressive systemic sclerosis (PSS) is a complex autoimmune disease.
- Bradykinin receptors (BK-R) play a role in various physiological processes.
- Altered receptor expression can contribute to disease pathogenesis.
Purpose of the Study:
- To investigate the expression and function of bradykinin receptors (BK-R) in dermal fibroblasts from PSS patients.
- To compare BK-R numbers and affinity in PSS fibroblasts versus healthy controls.
- To explore potential regulatory mechanisms of BK-R expression in PSS.
Main Methods:
- Receptor binding assays were used to quantify BK-R numbers and affinity.
- Northern blot hybridization with BK-R cDNA was employed to assess mRNA levels.
- Cultured dermal fibroblasts from PSS patients and healthy controls were analyzed.
Main Results:
- A significant reduction in the number of BK-R was observed in PSS fibroblasts compared to controls (P < 0.02).
- No significant differences in BK-R affinity were detected between the two groups.
- BK-R mRNA levels showed no significant differences, indicating normal transcription.
Conclusions:
- The decreased number of BK-R in PSS fibroblasts likely results from a post-translational modification.
- These findings suggest that post-translational regulation of BK-R is altered in progressive systemic sclerosis.
- Further research into these post-translational mechanisms could reveal new therapeutic targets for PSS.